CLOSE
MENU
Summary of Financial Results for the first quarter 2027
2026/08/07
サブ-ナビゲーション
【リダイレクト】
HOME
現在位置:
News Release
Company
Basic Philosophy
Top Message
Corporate Governance
Business Activities
Management Strategy
Company Outline
Board of Directors and Executive Officers
History
Office Locations
Affiliate Companies
Sustainability
Environmental Initiatives
Procurement Initiatives
Diversity Initiatives
Community Initiatives
Human Rights Initiatives
Sustainability Promotion Framework
Business Activities
Products
Gelatin
Collagen Peptide
Wellnex® DI-PEPTIDE
Wellnex® standard type
Food Material
Biomedical
Market/Application
Health Support
Biomedical
Cellmatrix
How to choose Cellmatrix Type I products
beMatrix
LET Gelatin
MedGel II
Other Products Line-up
Basic Knowledge
About Us
Wellcome
Brochure, Reference & Manual
Brochure & Reference
Safety Data Sheet
FAQ
Investor Relations
Corporate Governance
Financial Information
Financial Highlight (Full Year)
Financial Indicator (Consolidated)
IR Library
Earnings Reports
Annual Reports
Presentation
Disclosure Policy
IR Contact
Access
Web Institute
Biomedical Lab.
01. Living with the Cells
02. Expansion to medical field
03. Medical applications related to collagen and gelatin
Peptide Lab.
01. Basic Knowledge
02. Absorption
03. Skin
03. Skin (Clinical Trial)
03. Skin (Mechanism 1)
03. Skin (Mechanism 2)
04. Pressure Ulcer
04. Pressure Ulcer (Clinical Trial)
04. Pressure Ulcer (Mechanism)
05. Blood Vessel
06. Bone
07. Blood Sugar
08. Muscle
09. Joint
09. Joint (Clinical Trial)
09. Joint (Animal Studies)
09. Joint (Mechanism)
10. Video Library
Basic Information Security Policy
Privacy Policy
Cookie Policy
Basic Social Media Policy
Social Media Terms of Service
Contact Us
Corporate Contact
Biomedical Contact
Contact Us
Summary of Financial Results for the first quarter 2027
2026/08/07